Analysts Offer Predictions for KALV Q1 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for KalVista Pharmaceuticals in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst A. Fein expects that the specialty pharmaceutical company will earn ($0.69) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.46) EPS and Q4 2026 earnings at ($0.35) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to analysts’ expectations of $6.03 million.

KALV has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Citizens Jmp decreased their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. Finally, JMP Securities upped their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Friday, September 12th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.63.

KalVista Pharmaceuticals Stock Up 9.1%

KalVista Pharmaceuticals stock opened at $14.86 on Monday. The business’s 50-day moving average price is $12.15 and its 200 day moving average price is $12.82. The firm has a market cap of $751.11 million, a price-to-earnings ratio of -3.77 and a beta of -0.04. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $17.28.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Sherbrooke Park Advisers LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $191,000. Qube Research & Technologies Ltd increased its position in shares of KalVista Pharmaceuticals by 234.6% during the third quarter. Qube Research & Technologies Ltd now owns 325,435 shares of the specialty pharmaceutical company’s stock worth $3,964,000 after purchasing an additional 228,187 shares in the last quarter. Parkman Healthcare Partners LLC raised its stake in KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the last quarter. Brevan Howard Capital Management LP lifted its holdings in KalVista Pharmaceuticals by 319.1% in the 3rd quarter. Brevan Howard Capital Management LP now owns 55,878 shares of the specialty pharmaceutical company’s stock valued at $681,000 after purchasing an additional 42,545 shares in the last quarter. Finally, Creative Planning boosted its stake in KalVista Pharmaceuticals by 13.9% during the 3rd quarter. Creative Planning now owns 38,032 shares of the specialty pharmaceutical company’s stock worth $463,000 after purchasing an additional 4,652 shares during the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 3,328 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.55, for a total transaction of $38,438.40. Following the completion of the sale, the chief executive officer owned 398,981 shares of the company’s stock, valued at $4,608,230.55. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,336 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the transaction, the insider owned 122,505 shares of the company’s stock, valued at approximately $1,644,017.10. This trade represents a 1.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 30,184 shares of company stock valued at $413,348. 4.30% of the stock is owned by insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).